Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MPN Advances Day 2019 | Allo-transplant for myelofibrosis

Donal McLornan • 15 Nov 2019
MPN Advances Day 2019
Myelofibrosis Myeloproliferative Neoplasms

Donal McLornan, MB BCh, MRCP, PhD, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, discusses the retrospective study by the European Society for Blood and Marrow Transplantation (EBMT) Chronic Malignancies Working Party on myeloablative and reduced-intensity conditioning allo-transplant for myelofibrosis. This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.

More from Donal McLornan

1:29
EBMT CMWP data at ASH: MPN-U and second transplant
Donal McLornan • 15 Nov 2019

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals